Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | Daunorubicin and cytarabine approved for AML treatment within NHS Scotland

Zack Pemberton-Whiteley • 1 Apr 2019
BSH 2019
Acute Myeloid Leukemia Leukemia Cytarabine Daunorubicin

Daunorubicin and cytarabine were both recently approved by SMC for the treatment of AML within NHS Scotland. Zack Pemberton-Whiteley, Leukaemia Care, Worcester, UK, discusses this at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Zack Pemberton-Whiteley

5:21
The effect of COVID-19 on CLL patient experiences
Zack Pemberton-Whiteley • 10 Sep 2021
4:16
Improving patient communication in CLL
Zack Pemberton-Whiteley • 10 Sep 2021
0:43
Health technology assessments
Zack Pemberton-Whiteley • 15 Jun 2019
0:34
HARMONY project: an overview
Zack Pemberton-Whiteley • 15 Jun 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals